A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation

Inclusion Criteria: * Diagnosis as hepatocellular carcinoma (HCC) * Underwent liver transplantation and confirmed recurrent HCC post operation * Seropositive for hepatitis B surface antigen * No major post-operative complication * Life expectancy of at least 12 weeks * Ability to provide informed consent * Ability to comply with study procedures * HLA profile matching with HLA-class I restriction element of the available T cell receptors Exclusion Criteria: * Administration of any other cell therapy, including NK, CIK, DC, CTL, CAR-T, stem cells or combined therapy of the kind within 3 months prior to enrolment * Second primary malignancy that is clinically detectable at the time of consideration for study enrolment * Likelihood to require steroid treatment during the period of the clinical trial * Any other concurrent liver infections such as hepatitis A, C or D infection * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection * Known Central Nervous System tumours including metastatic brain disease. * Any condition that is unstable or which could jeopardise the safety of the patient and his/her compliance in the study * Patients with reproductive potential who tested positive for serum or urine pregnancy test result within 14 days prior to enrolment.